Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Prediction of docetaxel toxicity in older cancer patients: a Bayesian network approach.

Khayi F, Lafarge L, Terret C, Albrand G, Falquet B, Culine S, Gourgou S, Ducher M, Bourguignon L.

Fundam Clin Pharmacol. 2019 Apr 30. doi: 10.1111/fcp.12476. [Epub ahead of print]

PMID:
31038767
2.

A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Tod M, Goutelle S, Bleyzac N, Bourguignon L.

Clin Pharmacokinet. 2019 Apr;58(4):503-523. doi: 10.1007/s40262-018-0711-0.

PMID:
30194612
3.

Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.

Bourguignon LYW, Earle C, Shiina M.

Matrix Biol. 2019 May;78-79:180-200. doi: 10.1016/j.matbio.2018.07.008. Epub 2018 Aug 3.

PMID:
30077625
4.

Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.

Lafarge L, Khayi F, Bel-Kamel A, Charhon N, Sarfati L, Falquet B, Ducher M, Bourguignon L.

Drugs Aging. 2018 Jun;35(6):569-574. doi: 10.1007/s40266-018-0551-5.

PMID:
29882202
5.

[Proper use of fluoroquinolones in hospitalized elderly patients: Realisation of a clinical audit in geriatric hospitals of Lyon University Hospital].

Papailhau C, Gaujard S, Girard R, Bourguignon L, Mouchoux C.

Rev Med Interne. 2018 Jul;39(7):551-556. doi: 10.1016/j.revmed.2018.03.002. Epub 2018 May 18. French.

PMID:
29784465
6.

Determinants of amikacin first peak concentration in critically ill patients.

Boidin C, Jenck S, Bourguignon L, Torkmani S, Roussey-Jean A, Ledochowski S, Marry L, Ammenouche N, Dupont H, Marçon F, Allaouchiche B, Bohé J, Lepape A, Goutelle S, Friggeri A.

Fundam Clin Pharmacol. 2018 Dec;32(6):669-677. doi: 10.1111/fcp.12374. Epub 2018 May 23.

PMID:
29660162
7.

A Middle Palaeolithic wooden digging stick from Aranbaltza III, Spain.

Rios-Garaizar J, López-Bultó O, Iriarte E, Pérez-Garrido C, Piqué R, Aranburu A, Iriarte-Chiapusso MJ, Ortega-Cordellat I, Bourguignon L, Garate D, Libano I.

PLoS One. 2018 Mar 28;13(3):e0195044. doi: 10.1371/journal.pone.0195044. eCollection 2018.

8.

Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Fermier N, Bourguignon L, Goutelle S, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Dec;57(12):1581-1591. doi: 10.1007/s40262-018-0651-8.

PMID:
29572664
9.

[Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach].

Lafarge L, Bourguignon L, Bernard N, Vial T, Dehan-Moya MJ, De La Gastine B, Goutelle S.

Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):91-97. doi: 10.1016/j.ancard.2018.02.001. Epub 2018 Mar 12. French.

PMID:
29544975
10.

Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.

Cazaubon Y, Venisse N, Mimoz O, Maire P, Ducher M, Bourguignon L, Goutelle S.

J Antimicrob Chemother. 2017 Oct 1;72(10):2804-2812. doi: 10.1093/jac/dkx242.

PMID:
29091222
11.

Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.

Bourguignon LYW, Earle C, Shiina M.

Int J Mol Sci. 2017 Aug 24;18(9). pii: E1849. doi: 10.3390/ijms18091849. Review.

12.

Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model.

Pouzot-Nevoret C, Magnin M, Ayoub JY, Bourguignon L, Maire P, Wertz D, Goy-Thollot I, Barthélemy A, Boselli E, Allaouchiche B, Bonnet-Garin JM.

Int J Antimicrob Agents. 2017 Aug;50(2):148-154. doi: 10.1016/j.ijantimicag.2017.03.029. Epub 2017 Jul 6.

PMID:
28689868
13.

Risk factors for urinary tract infections in geriatric hospitals.

Girard R, Gaujard S, Pergay V, Pornon P, Martin-Gaujard G, Bourguignon L; UTIC Group.

J Hosp Infect. 2017 Sep;97(1):74-78. doi: 10.1016/j.jhin.2017.05.007. Epub 2017 May 16.

PMID:
28526270
14.

Mechanisms of drug-drug interaction between rifampicin and fusidic acid.

Bel F, Bourguignon L, Tod M, Ferry T, Goutelle S.

Br J Clin Pharmacol. 2017 Aug;83(8):1862-1864. doi: 10.1111/bcp.13277. Epub 2017 Apr 12. No abstract available.

15.

Factors associated with changes in exposure to anticholinergic and sedative medications in elderly hospitalized patients: multicentre longitudinal study.

Dauphinot V, Faure R, Bourguignon L, Goutelle S, Krolak-Salmon P, Mouchoux C.

Eur J Neurol. 2017 Mar;24(3):483-490. doi: 10.1111/ene.13228. Epub 2016 Dec 27.

PMID:
28026898
16.

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?

Tod M, Goutelle S, Bourguignon L, Bleyzac N.

CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):226. doi: 10.1002/psp4.12164. Epub 2017 Apr 11. No abstract available.

17.

A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

Tod M, Bourguignon L, Bleyzac N, Goutelle S.

AAPS J. 2017 Mar;19(2):497-509. doi: 10.1208/s12248-016-0021-0. Epub 2016 Dec 6.

PMID:
27924615
18.

Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients.

Bel Kamel A, Bourguignon L, Marcos M, Ducher M, Goutelle S.

Ther Drug Monit. 2017 Feb;39(1):83-87. doi: 10.1097/FTD.0000000000000359.

PMID:
27861313
19.

Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.

Bourguignon L, Cazaubon Y, Debeurme G, Loue C, Ducher M, Goutelle S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4563-7. doi: 10.1128/AAC.00303-16. Print 2016 Aug.

20.

Matrix Hyaluronan Promotes Specific MicroRNA Upregulation Leading to Drug Resistance and Tumor Progression.

Bourguignon LY.

Int J Mol Sci. 2016 Apr 7;17(4):517. doi: 10.3390/ijms17040517. Review.

21.

Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study.

Lalande L, Bourguignon L, Maire P, Goutelle S.

J Theor Biol. 2016 Jun 21;399:43-52. doi: 10.1016/j.jtbi.2016.03.038. Epub 2016 Apr 5.

PMID:
27059890
23.

Selective Activation of Cancer Stem Cells by Size-Specific Hyaluronan in Head and Neck Cancer.

Shiina M, Bourguignon LY.

Int J Cell Biol. 2015;2015:989070. doi: 10.1155/2015/989070. Epub 2015 Sep 10.

24.

Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.

Cazaubon Y, Bourguignon L, Goutelle S, Martin O, Maire P, Ducher M.

Fundam Clin Pharmacol. 2015 Dec;29(6):615-24. doi: 10.1111/fcp.12156. Epub 2015 Oct 26.

PMID:
26406268
25.

A Bayesian Model to Describe Factors Influencing Trough Levels of Vancomycin in Hemodialysis Patients.

Sansot C, Kalbacher E, Lemoine S, Bourguignon L, Fauvel JP, Ducher M.

Nephron. 2015;131(2):131-7. doi: 10.1159/000439230. Epub 2015 Sep 17.

PMID:
26376164
26.

Preliminary data on pupal development, lifespan and fertility of Cynomyamortuorum (L., 1761) in Belgium (Diptera: Calliphoridae).

Braet Y, Bourguignon L, Vanpoucke S, Drome V, Hubrecht F.

Biodivers Data J. 2015 Jul 31;(3):e5387. doi: 10.3897/BDJ.3.e5387. eCollection 2015.

27.

Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Lalande L, Bourguignon L, Bihari S, Maire P, Neely M, Jelliffe R, Goutelle S.

Antimicrob Agents Chemother. 2015 Sep;59(9):5181-9. doi: 10.1128/AAC.00462-15. Epub 2015 Jun 15.

28.
29.

Identification of novel drugs to target dormant micrometastases.

Hurst RE, Hauser PJ, You Y, Bailey-Downs LC, Bastian A, Matthews SM, Thorpe J, Earle C, Bourguignon LY, Ihnat MA.

BMC Cancer. 2015 May 14;15:404. doi: 10.1186/s12885-015-1409-4.

30.

New developmental data for Cynomya mortuorum (L., 1761) in Belgium (Diptera: Calliphoridae).

Braet Y, Bourguignon L, Vanpoucke S, Drome V, Hubrecht F.

Forensic Sci Int. 2015 Jul;252:29-32. doi: 10.1016/j.forsciint.2015.04.018. Epub 2015 Apr 22.

PMID:
25933426
31.

Controlling urinary tract infections associated with intermittent bladder catheterization in geriatric hospitals.

Girard R, Gaujard S, Pergay V, Pornon P, Martin Gaujard G, Vieux C, Bourguignon L; Urinary Tract Infection Control Group.

J Hosp Infect. 2015 Jul;90(3):240-7. doi: 10.1016/j.jhin.2015.02.008. Epub 2015 Mar 5.

PMID:
25799483
32.

Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely MN, Goutelle S.

Antimicrob Agents Chemother. 2015;59(6):2986-94. doi: 10.1128/AAC.04132-14. Epub 2015 Mar 9.

33.

The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy.

Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely MN.

Curr Pharm Des. 2014;20(39):6191-206. Review.

PMID:
25190098
34.

Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort.

Dauphinot V, Faure R, Omrani S, Goutelle S, Bourguignon L, Krolak-Salmon P, Mouchoux C.

J Clin Psychopharmacol. 2014 Oct;34(5):565-70. doi: 10.1097/JCP.0000000000000195. Erratum in: J Clin Psychopharmacol. 2017 Feb;37(1):26.

PMID:
25133790
35.

Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression.

Bourguignon LY, Shiina M, Li JJ.

Adv Cancer Res. 2014;123:255-75. doi: 10.1016/B978-0-12-800092-2.00010-1. Review.

PMID:
25081533
36.

Matrix hyaluronan-activated CD44 signaling promotes keratinocyte activities and improves abnormal epidermal functions.

Bourguignon LY.

Am J Pathol. 2014 Jul;184(7):1912-9. doi: 10.1016/j.ajpath.2014.03.010. Epub 2014 May 9. Review.

37.
38.

Study of relationship between volume of distribution and body weight application to amikacin.

Rughoo L, Bourguignon L, Maire P, Ducher M.

Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):87-91. doi: 10.1007/s13318-013-0160-y. Epub 2014 Mar 6.

PMID:
24599705
39.

The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.

Chan JK, Blansit K, Kiet T, Sherman A, Wong G, Earle C, Bourguignon LY.

Gynecol Oncol. 2014 Mar;132(3):739-44. doi: 10.1016/j.ygyno.2014.01.034. Epub 2014 Jan 25.

PMID:
24472409
40.

Utility of GenBank and the Barcode of Life Data Systems (BOLD) for the identification of forensically important Diptera from Belgium and France.

Sonet G, Jordaens K, Braet Y, Bourguignon L, Dupont E, Backeljau T, De Meyer M, Desmyter S.

Zookeys. 2013 Dec 30;(365):307-28. doi: 10.3897/zookeys.365.6027. eCollection 2013 Dec 30.

41.

DNA barcoding and the differentiation between North American and West European Phormia regina (Diptera, Calliphoridae, Chrysomyinae).

Jordaens K, Sonet G, Braet Y, De Meyer M, Backeljau T, Goovaerts F, Bourguignon L, Desmyter S.

Zookeys. 2013 Dec 30;(365):149-74. doi: 10.3897/zookeys.365.6202. eCollection 2013 Dec 30.

42.

Evidence supporting an intentional Neandertal burial at La Chapelle-aux-Saints.

Rendu W, Beauval C, Crevecoeur I, Bayle P, Balzeau A, Bismuth T, Bourguignon L, Delfour G, Faivre JP, Lacrampe-Cuyaubère F, Tavormina C, Todisco D, Turq A, Maureille B.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):81-6. doi: 10.1073/pnas.1316780110. Epub 2013 Dec 16.

43.

The fragmented character of Middle Palaeolithic stone tool technology.

Turq A, Roebroeks W, Bourguignon L, Faivre JP.

J Hum Evol. 2013 Nov;65(5):641-55. doi: 10.1016/j.jhevol.2013.07.014. Epub 2013 Sep 26.

PMID:
24074611
44.

[Inter-individual and intra-individual pharmacokinetic variability during teicoplanin therapy in geriatric patients].

Uhart M, Leroy B, Michaud A, Maire P, Bourguignon L.

Med Mal Infect. 2013 Jul;43(7):295-8. doi: 10.1016/j.medmal.2013.05.008. Epub 2013 Jul 29. French.

PMID:
23906420
45.

Selective matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes keratinocyte functions and overcomes age-related epidermal dysfunction.

Bourguignon LY, Wong G, Xia W, Man MQ, Holleran WM, Elias PM.

J Dermatol Sci. 2013 Oct;72(1):32-44. doi: 10.1016/j.jdermsci.2013.05.003. Epub 2013 Jun 5.

46.

Guidelines for aminoglycoside use and applicability to geriatric patients.

Uhart M, Leroy B, Maire P, Bourguignon L.

Med Mal Infect. 2013 Mar;43(3):118-22. doi: 10.1016/j.medmal.2012.12.006. Epub 2013 Apr 4.

PMID:
23562282
47.

[Calculation of the first dose of amikacine: evaluation of the current dosage recommendations].

Jean-Bart E, Debeurme G, Ducher M, Bourguignon L.

Ann Pharm Fr. 2013 Jan;71(1):7-12. doi: 10.1016/j.pharma.2012.10.002. Epub 2012 Nov 13. French.

PMID:
23348851
48.

Bayesian networks: a new method for the modeling of bibliographic knowledge: application to fall risk assessment in geriatric patients.

Lalande L, Bourguignon L, Carlier C, Ducher M.

Med Biol Eng Comput. 2013 Jun;51(6):657-64. doi: 10.1007/s11517-013-1035-8. Epub 2013 Jan 20.

PMID:
23334773
49.

In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M.

AAPS J. 2013 Apr;15(2):415-26. doi: 10.1208/s12248-012-9431-9. Epub 2013 Jan 15.

50.

[Practical application of the charter of pharmaceutical sales visit].

Leroy B, Uhart M, Lajoinie A, Maire P, Ducher M, Bourguignon L.

Ann Pharm Fr. 2012 Nov;70(6):348-52. doi: 10.1016/j.pharma.2012.06.001. Epub 2012 Jul 25. French.

PMID:
23177561

Supplemental Content

Loading ...
Support Center